{"id":"W2948726637","doi":"10.1016/s0140-6736(19)30650-6","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Health Economics","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research; University of Warwick; Cancer Research UK; University of Cambridge; Department of Health and Social Care","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical endpoint; Internal medicine; Intention-to-treat analysis; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy; Adjuvant; Cancer; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004834649,0.001482618,0.00221702,0.0004107205,0.0003334876,0.0008789535,0.0007725456,0.002075213,0.007191629],"category_scores_gemma":[0.004164773,0.0004752815,0.002619363,0.000360225,0.001195799,0.00113992,0.0004397056,0.002249701,0.0008604209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006914245,"about_ca_system_score_gemma":0.0009132443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000486859,"about_ca_topic_score_gemma":0.0009970089,"domain_scores_codex":[0.9981486,0.00132861,0.00009070165,0.0001782622,0.00008614273,0.0001677965],"domain_scores_gemma":[0.9974833,0.001068543,0.0006819596,0.0002004587,0.00009801025,0.0004677502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9873915,0.002852875,0.0002893661,0.0003016664,0.0004477734,0.00002266445,0.00004061605,0.0001940787,0.0008810314,0.00004292107,0.0002544478,0.007281095],"study_design_scores_gemma":[0.9508998,0.04678125,0.001241459,0.00003686098,0.0003186125,0.00002428542,0.00001089243,0.0001800976,0.0001513794,0.0001159135,0.0002299401,0.000009598333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877743,0.004984865,0.0005601247,0.000715517,0.0003890019,0.003088222,0.0006676619,0.00005883494,0.001761461],"genre_scores_gemma":[0.9835839,0.002988972,0.001552822,0.001396329,0.0005551768,0.005448194,0.0008209709,0.00003364786,0.003620094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007191629,"threshold_uncertainty_score":0.02556837,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05371163214208088,"score_gpt":0.3732203289132454,"score_spread":0.3195086967711646,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}